8-K current report · filed Nov 3, 2026

Nurix Therapeutics, Inc. (NRIX) 8-K Current Report: November 3, 2026

Item 8.01NRIX overview

Short answer

Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 8.01 (Other Events). Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader.

Nurix Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader
  • Nurix loses eligibility for future development, regulatory and commercial milestones and royalties tied to SAR448272
  • Remaining Sanofi collaboration programs retain potential milestone and royalty value
  • Sanofi retains discretion over advancing other licensed programs, leaving broader partnership economics uncertain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nurix Therapeutics, Inc. 8-K filings

Get the next NRIX 8-K as it lands

Follow NRIX for push alerts, or ask the research agent what this filing means.